COVID-19 International Drug Pregnancy Registry
This study is an international registry looking at the effects of COVID-19 treatments on pregnant women and their babies. Researchers want to understand how antiviral agents and monoclonal antibodies, used to treat mild to severe COVID-19 during pregnancy, impact mothers and their infants. They will track outcomes like complications during pregnancy (obstetric outcomes), issues with the newborn (neonatal outcomes), and the baby's weight for up to one year after birth. You may be able to join if you are a woman aged 18 to 50, are pregnant or recently pregnant (within 30 days after delivery), had mild to severe COVID-19 during pregnancy, and were treated with one of these medications. The study aims to enroll 2000 participants.
- Study design
- This is an observational study, meaning researchers will collect information without giving you a specific treatment. It plans to include 2000 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your obstetric, neonatal, and infant outcomes will be measured for up to one year after birth.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
COVID-19 International Drug Pregnancy Registry
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Cheryl Renz, MD · PRINCIPAL_INVESTIGATOR · Pregistry
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Obstetric outcomes1 year
Number of pregnant women who received at least one dose of a monoclonal antibody or antiviral drug indicated for the treatment of mild, moderate, or severe COVID-19 and number of pregnant women in the reference cohorts who experience spontaneous abortion, intrauterine growth restriction, gestational diabetes, gestational hypertension, postpartum hemorrhage, Caesarean delivery.
- Neonatal outcomes1 year
Number of newborns of women who received at least one dose of a monoclonal antibody or antiviral drug indicated for the treatment of mild, moderate, or severe COVID-19 and number of newborns of pregnant women in the reference cohorts who experience major congenital malformations, low birth weight, small for gestational age, neonatal infections, stillbirth, neonatal death, preterm birth.
- Infant weight1 year
Change in weight from birth to 3, 6, 9, and 12 months of age among newborns of women who received at least one dose of a monoclonal antibody or antiviral drug indicated for the treatment of mild, moderate, or severe COVID-19 and among newborns of pregnant women in the reference cohorts.
- Infant developmental milestones1 year
Change in developmental milestones from baseline at 6, 9, and 12 months based on the tool Caregiver Reported Early Development Instruments among the offspring of women who received at least one dose of a monoclonal antibody or antiviral drug indicated for the treatment of mild, moderate, or severe COVID-19 and among the offspring of pregnant women in the reference cohorts.
- Infant height1 year
Change in length from birth to 3, 6, 9, and 12 months of age among newborns of women who received at least one dose of a monoclonal antibody or antiviral drug indicated for the treatment of mild, moderate, or severe COVID-19 and among newborns of pregnant women in the reference cohorts.